Entrectinib for Locally Advanced or Metastatic ROS1 Fusion–Positive NSCLC
Posted: Wednesday, December 20, 2017
Entrectinib, an investigational, oral inhibitor of ROS1, appeared to be well tolerated and showed antitumor activity in patients with ROS1 fusion–positive advanced non–small cell lung cancer (NSCLC), according to study findings presented by Myung-Ju Ahn, MD, of the Department of Hematology & Oncology, Samsung Medical Center, at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 14.06) in Yokohama, Japan.
Furthermore, "entrectinib demonstrated strong central nervous system [CNS] activity; the response rate was 83% in patients with measurable CNS disease at baseline,” commented Dr. Ahn in an IASLC press release.
Patients with ROS1 inhibitor–naive NSCLC were enrolled across phase I and II studies of entrectinib. Treatment was administered orally at 600 mg once daily in 4-week cycles.
As of late May 2017, 32 patients were evaluable for response. After a median follow-up of 12 months, treatment with entrectinib induced an objective response rate of 68.8% (including 2 complete responses) on blinded independent central review. The most common treatment-related adverse events were fatigue/asthenia, dysgeusia, dizziness, and weight increase, with the majority of treatment-related adverse events being grade 1 or 2.
